Inhibitors of ALDH4A1 could also potentially be used as pharmacological chaperones [14,15] to stabilize the misfolded variants of ALDH4A1 produced in patients with hyperprolinemia II, a metabolic disorder caused by mutations in the ALDH4A1 gene which can result in neurological problems, including intellectual disability [16,17]. The gene discussed is ALDH4A1; the disease is Other metabolic disease.